Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunochemotherapy for Richter syndrome: current insights.
Puła B, Salomon-Perzyński A, Prochorec-Sobieszek M, Jamroziak K. Puła B, et al. Among authors: jamroziak k. Immunotargets Ther. 2019 Feb 5;8:1-14. doi: 10.2147/ITT.S167456. eCollection 2019. Immunotargets Ther. 2019. PMID: 30788335 Free PMC article. Review.
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
Góra-Tybor J, Gołos A, Mikulski D, Helbig G, Sacha T, Lewandowski K, Niesiobędzka-Krężel J, Bieniaszewska M, Wysogląd H, Grzybowska-Izydorczyk O, Seferyńska I, Sobas M, Czyżewska M, Michalska A, Sawicki W, Mazur M, Hus M, Bodzenta E, Olszewska-Szopa M, Włodarczyk M, Patkowska E, Świstek W, Jamroziak K. Góra-Tybor J, et al. Among authors: jamroziak k. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e19-e26. doi: 10.1016/j.clml.2022.10.002. Epub 2022 Oct 22. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36396583
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer.
Campa D, Gentiluomo M, Stein A, Aoki MN, Oliverius M, Vodičková L, Jamroziak K, Theodoropoulos G, Pasquali C, Greenhalf W, Arcidiacono PG, Uzunoglu F, Pezzilli R, Luchini C, Puzzono M, Loos M, Giaccherini M, Katzke V, Mambrini A, Kiudeliene E, Federico KE, Johansen J, Hussein T, Mohelnikova-Duchonova B, van Eijck CHJ, Brenner H, Farinella R, Pérez JS, Lovecek M, Büchler MW, Hlavac V, Izbicki JR, Hackert T, Chammas R, Zerbi A, Lawlor R, Felici A, Götz M, Capurso G, Ginocchi L, Gazouli M, Kupcinskas J, Cavestro GM, Vodicka P, Moz S, Neoptolemos JP, Kunovsky L, Bojesen SE, Carrara S, Gioffreda D, Morkunas E, Abian O, Bunduc S, Basso D, Boggi U, Wlodarczyk B, Szentesi A, Vanella G, Chen I, Bijlsma MF, Kiudelis V, Landi S, Schöttker B, Corradi C, Giese N, Kaaks R, Peduzzi G, Hegyi P, Morelli L, Furbetta N, Soucek P, Latiano A, Talar-Wojnarowska R, Lindgaard SC, Dijk F, Milanetto AC, Tavano F, Cervena K, Erőss B, Testoni SG, Verhagen-Oldenampsen JHE, Małecka-Wojciesko E, Costello E, Salvia R, Maiello E, Ermini S, Sperti C, Holleczek B, Perri F, Skieceviciene J, Archibugi L, Lucchesi M, Rizzato C, Canzian F. Campa D, et al. Among authors: jamroziak k. Crit Rev Oncol Hematol. 2023 Jun;186:104020. doi: 10.1016/j.critrevonc.2023.104020. Epub 2023 May 8. Crit Rev Oncol Hematol. 2023. PMID: 37164172 Free article. Review.
Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K, Puła B, Walewski J. Jamroziak K, et al. Curr Treat Options Oncol. 2017 Jan;18(1):5. doi: 10.1007/s11864-017-0448-2. Curr Treat Options Oncol. 2017. PMID: 28185174 Review.
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B, Budziszewska BK, Rybka J, Gil L, Subocz E, Długosz-Danecka M, Zawirska D, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Kopacz A, Szymczyk A, Czyż J, Lech-Marańda E, Warzocha K, Jamroziak K. Puła B, et al. Among authors: jamroziak k. Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557. Anticancer Res. 2018. PMID: 29715135
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A, Walter-Croneck A, Usnarska-Zubkiewicz L, Dytfeld D, Zielińska P, Wojciechowska M, Hołojda J, Robak P, Pasternak A, Knopińska-Posłuszny W, Hawrylecka D, Wójtowicz M, Szeremet A, Osowiecki M, Mordak-Domagała M, Zaucha JM, Giannopoulos K, Warzocha K, Jamroziak K. Salomon-Perzyński A, et al. Among authors: jamroziak k. Adv Med Sci. 2019 Sep;64(2):349-355. doi: 10.1016/j.advms.2019.05.001. Epub 2019 May 21. Adv Med Sci. 2019. PMID: 31125864
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E, Puła B, Szeremet A, Hus M, Gołos A, Hołojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Zaucha JM, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Among authors: jamroziak k. Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911. Adv Clin Exp Med. 2019. PMID: 31199879 Free article.
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Puła B, Gołos A, Górniak P, Jamroziak K. Puła B, et al. Among authors: jamroziak k. Cancers (Basel). 2019 Nov 21;11(12):1834. doi: 10.3390/cancers11121834. Cancers (Basel). 2019. PMID: 31766355 Free PMC article. Review.
142 results